What Аллокин-альфа Treats: Main Uses and Benefits

This medication is considered relevant for supportive management in conditions characterized by periods of heightened symptoms arising from specific viral infections, such as those that manifest with noticeable, recurrent, or persistent symptoms. It is commonly used to help with conditions involving recurrent episodes of herpes-viral infections and viral hepatitis B.

Symptomatic Support for Viral Conditions

This treatment is applied in situations involving certain distressing symptoms arising from recurrent outbreaks, such as those that cause blisters, sores, or lesions on the skin and mucous membranes. It is also relevant for easing symptoms related to systemic imbalance like feelings of prolonged fatigue and general malaise associated with persistent viral activity. This usage is applicable within clinical settings that involve acute or disruptive symptom patterns.

The active substance is relevant for easing symptoms related to herpes-viral infections and viral hepatitis B. This type of supportive care helps patients cope more steadily with these persistent manifestations.

Quick Fact: Relevant for Symptoms Associated with Recurrent Episodes

“The supportive care provided may assist with maintaining functional stability and help patients cope more steadily with symptom fluctuations.”

This medication may assist with maintaining a sense of stability and supports patients during episodes of heightened discomfort by addressing symptoms that create noticeable functional strain.

Who can and cannot use Аллокин-альфа?

The official regulatory documents define the population eligible to use Аллокин-альфа primarily by listing absolute contraindications. The medicine is authorized for use only in the adult population, meaning individuals 18 years of age and older who do not have any documented contraindications.

---

Eligibility Scope

Classification	Official Regulatory Statement
Populations Allowed	Adults aged 18 years and older who meet no contraindications.
Populations Contraindicated	Individuals under 18; those with hypersensitivity to Alloferon; patients with expressed or severe autoimmune diseases.

---

Absolute Contraindications

Use is strictly prohibited for several specific populations. The medicine is contraindicated for all children and adolescents under 18 years.

Furthermore, the drug is absolutely contraindicated in patients with a known history of hypersensitivity to Alloferon or any excipients, and in those diagnosed with expressed or severe autoimmune diseases.

Regarding reproductive status, the medication is explicitly contraindicated during both pregnancy and throughout the period of lactation (breastfeeding). If treatment is required, official instructions mandate the cessation of breastfeeding. No general restrictions related to mild or moderate hepatic or renal impairment are documented as absolute contraindications in the core label.

Interactions with other medicines and products

Official regulatory information for Аллокин-альфа (Alloferon) provides specific guidance regarding combination use while noting the formal absence of identified general interaction risks.

Documented Interaction Status

Interaction Type	Regulatory Status (Official Documentation)
Pharmacokinetic (e.g., CYP-mediated)	Not identified (Formally stated as "Interactions with other medicinal products have not been identified")
Transporter-Mediated	Not identified
Contraindicated Combinations	None documented in regulatory labeling
Food, Alcohol, or Supplements	None documented

Officially Approved Combination Use

The regulatory profile explicitly permits co-administration with specific antiviral treatments, reflecting the product's intended use in supportive management of viral conditions. This permission constitutes the primary interaction information available in prescribing documents:

• Aciclovir: The medicine is explicitly approved for use in combination with aciclovir for the treatment of chronic recurrent genital herpes.
• Standard Treatment: For the management of acute hepatitis B, the medicine is sanctioned for use against the background of generally accepted basic therapy for that condition.

Interaction-Related Restrictions

No mandatory restrictions, such as dose separation rules or timing requirements, are documented in the official regulatory information. The focus remains on the explicit authorization of co-administration within defined therapeutic contexts.

Аллокин-альфа exerts its pharmacodynamic action by targeting the innate immune system. The active oligopeptide, alloferon, engages specific receptors on immune cells, including Natural Killer ( NK) cells and monocytes. This molecular interaction triggers an intracellular signaling cascade that primarily results in two mechanistic consequences.

First, the compound functions as an inducer of endogenous interferon ( IFN) synthesis. This promotes the accelerated production and release of IFN-alpha and IFN-gamma. The secreted IFNs subsequently establish an antiviral state in local and peripheral cells and modulate the immune cell environment.

Second, Аллокин-альфа directly activates NK cells, enhancing their cytotoxic potential. This is mediated by an upregulation of lytic proteins, such as perforin and granzyme B, which are released to induce apoptosis in targeted defective cells. The combined action of IFN induction and NK cell activation influences the subsequent maturation and cytotoxic activity of Cytotoxic T Lymphocytes ( CTLs), thereby amplifying the cellular immune response system-wide.

The administration of Alloferon is defined by a specific, standardized protocol. The medication is supplied as a lyophilizate, a powder that requires reconstitution immediately before use. The process involves mixing the 1.0 mg contents of the ampoule with precisely 1 ml of 0.9% sterile sodium chloride solution (NaCl) to prepare the injectable solution. The route of delivery for this preparation is subcutaneous injection, which is administered under the skin by a healthcare professional.

Dosing is standardized at 1.0 mg per injection, with the overall regimen determined by the specific condition being addressed. The frequency of use follows an intermittent, cyclic pattern. For recurrent herpes simplex infection, the therapeutic course consists of three total injections administered every other day, with treatment initiation starting at the onset of the disease's first signs.

A longer course is specified for the management of Human Papillomavirus (HPV) infection, which involves a total of six injections also administered on an every-other-day schedule. For acute Hepatitis B, the regimen requires a total of nine injections administered three times per week over a three-week period. For this indication, administration commences no later than seven days following the development of jaundice. There are no specific guidelines for dose adjustment in older adult populations.

Аллокин-альфа: Recent Clinical Evidence

The following summary outlines key findings from published clinical and non-clinical research that has investigated the use of the peptide Allokin-alpha (containing the active ingredient alloferon) in certain viral conditions.

---

Studies in Human Papillomavirus (HPV) Infection

Research has primarily focused on the use of Allokin-alpha as a component of combination therapy for Human Papillomavirus (HPV) infection, including cases associated with cervical intraepithelial neoplasia (CIN) grades 1 and 2.

Studies investigated the effect on viral load and the frequency of viral elimination. In trials focused on HPV-associated CIN, specific findings included:

• HPV Elimination: One study reported that the use of Allokin-alpha therapy, followed by excision, led to a greater frequency of HPV elimination than excision alone, with a notable reduction in viral load observed before the surgical procedure.
• CIN 1: Research investigating the compound's effect in patients with HPV-associated CIN 1 indicated that viral DNA was below the detection threshold in a majority of treated patients after 12 months, compared to the observation group.

---

Research in Chronic Herpesvirus Infections

Clinical research has also explored the compound's effect in patients diagnosed with chronic Epstein-Barr Virus (EBV) infection. Specific findings include:

• EBV DNA Load: In comparative studies, treatment was associated with a reduction in the EBV DNA copy number in saliva samples, a finding that was observed in a larger percentage of patients compared to those receiving other antiviral agents.
• Immunological Changes: The research noted that treatment was associated with an expansion of Natural Killer (NK) cells and changes in their cytotoxic activity, which are components of the body's innate immune response. The compound is understood to act by stimulating the immune system, including promoting the production of interferons, which are signaling proteins involved in antiviral defense.

Common questions about Аллокин-альфа (FAQ)

Q: What is the primary difference between Аллокин-альфа and standard antiviral treatments?

The official product information describes this medicine as an immunomodulatory agent. Its mechanism of action involves stimulating the body's own immune system, specifically by increasing the production of natural proteins called interferons and activating key cells like Natural Killer (NK) cells. This approach differs from that of some standard antiviral treatments, which may instead target the virus directly.

Q: Does this drug interact with common over-the-counter or prescription medicines?

Official regulatory documents indicate that general pharmacokinetic interactions with other medicinal products have not been identified. This status applies to both commonly prescribed medications, such as blood pressure drugs, and over-the-counter products. Furthermore, the label does not document any other drug reducing the anticipated effects of Аллокин-альфа.

Q: Why is a specific administration route (subcutaneous injection) used for this drug?

The active substance, alloferon, is defined as a synthetic oligopeptide—a short chain of amino acids. Due to the molecular structure of peptides, this medicine is administered via subcutaneous injection (under the skin) as this route is required for the drug's intended action. This route is required due to the molecular structure, as similar peptide molecules are typically broken down by the digestive system if taken orally.

Q: Is it possible to use Аллокин-альфа if a patient has a serious kidney or liver issue?

Official prescribing documents do not list general restrictions for mild or moderate kidney (renal) or liver (hepatic) impairment as absolute contraindications. The official documentation is primarily focused on contraindications and eligibility criteria, and does not provide detailed specific guidance for patients with serious or severe impairment.

Q: How does the body process and eliminate Аллокин-альфа? (Pharmacokinetics)

The active substance is an oligopeptide, which is a molecule made of amino acids. This type of compound is typically processed and eliminated by the body using the natural metabolic pathways that handle other proteins. This is consistent with how the body handles similar peptide molecules.

Q: What official safety classification does Аллокин-альфа fall under?

According to the official regulatory information, Аллокин-альфа is classified as a prescription-only medicinal product. It is indicated for use in the adult population, meaning individuals 18 years of age and older.

Q: Is the active ingredient in Аллокин-альфа naturally occurring in the body?

No. The active substance, alloferon, is specifically defined in regulatory documentation as a synthetic oligopeptide. This means it is a short chain of amino acids that is created synthetically, distinguishing it from naturally derived biological preparations.

Q: Why does the treatment sometimes involve multiple sequential uses over time?

The treatment is administered on an intermittent, cyclic schedule over several days or weeks, depending on the specific condition being addressed. This pattern aligns with the biological action of the drug, which involves stimulating the production of proteins like interferons over a specific duration.

Official Storage and Disposal Requirements

Аллокин-альфа (Allokin-alpha) must be stored under specific, mandatory conditions to maintain its stability, as defined by regulatory labeling.

Storage Conditions

Requirement	Official Instruction
Temperature Range	Store in a refrigerator between 2 C and 8 C.
Protection	Keep in the original factory packaging, protected from light.
Prohibited	The product must not be frozen.
Post-Reconstitution	The prepared injection solution must be used immediately.

Disposal and Safety

Unused or expired product must not be disposed of in household trash or wastewater. Disposal should follow established local regulatory requirements for pharmaceutical waste. As with all medications, the ampoules must be kept strictly out of the sight and reach of children.